Physician profile
Robert A Dye
NPI 1225077217
$14,182.93
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,589 · 2020: $1,327 · 2021: $3,514 · 2022: $2,622 · 2023: $3,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,112 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,111.58 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $4,368.11 | 2019-2023 | Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $1,527.62 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $1,318.61 | 2019-2023 | Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $1,267.84 | 2020-2023 | Nexletol |
| Amgen INC. | $1,126.57 | 2019-2021 | |
| Glaxosmithkline, LLC. | $775.19 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $732.10 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $574.40 | 2020-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $511.27 | 2019-2023 | Camzyos, Eliquis |
| Pfizer INC. | $477.72 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $390.47 | 2019-2023 | Verquvo |
| Lilly USA, LLC | $305.83 | 2019-2021 | |
| Abbvie INC. | $257.02 | 2022-2023 | Ubrelvy, Qulipta |
| Janssen Biotech, INC. | $184.90 | 2022-2023 | Simponi Aria |
| Abiomed | $123.80 | 2023 | Impella |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $99.77 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $71.64 | 2019 | |
| Exact Sciences Corporation | $55.54 | 2023 | Cologuard Collection Kit |
| Corium, LLC | $14.53 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.